Cindy Reiss-Clark, VP & GM of West‘s (NYSE:WST) global biologics business, comments on the drug delivery trends that stood out from 2018 and what she’s keeping an eye on in the coming year.
What were the trends that drove the biopharma and drug delivery markets in 2018?
Many of 2018’s key trends revolved around increasing regulatory requirements. However, as the market continues to move toward more personalized medicine, such as cell and gene therapies, the overall cost of health care is a driving factor. While the majority of large patient population indications, including diabetes and rheumatoid arthritis, have available biologic treatments, there are exceptions.
Get the full story at our sister site, Drug Delivery Business News.
The post What’s ahead for the drug delivery market in 2019? appeared first on MassDevice.